Pharmacokinetic profile of zafirlukast.

@article{Dekhuijzen2002PharmacokineticPO,
  title={Pharmacokinetic profile of zafirlukast.},
  author={P. N. Richard Dekhuijzen and Peter P. Koopmans},
  journal={Clinical pharmacokinetics},
  year={2002},
  volume={41 2},
  pages={105-14}
}
Zafirlukast is a cysteinyl leukotriene type 1 receptor antagonist that causes bronchodilation and has anti-inflammatory properties. Clinical efficacy has been demonstrated when using oral doses of 20 to 40 mg twice daily. The pharmacokinetics of zafirlukast are best described by a two-compartment model. Maximum plasma concentrations (Cmax) were achieved 3 hours after a single oral dose of 20 or 40 mg to healthy volunteers. The absolute bioavailability of zafirlukast is unknown. However… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 18 extracted citations

Similar Papers

Loading similar papers…